Search Patents
  • CORONAVIRUS VACCINE FORMULATIONS
    Publication number: 20240165221
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Application
    Filed: December 1, 2023
    Publication date: May 23, 2024
    Inventors: Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
  • Corona-virus-like particles comprising functionally deleted genomes
    Publication number: 20040071709
    Abstract: The invention relates to the field of coronaviruses and diagnosis, therapeutics, and vaccines derived thereof. Methods are shown for at least in part inhibiting anti-parallel coiled coil formation of a coronavirus spike protein wherein the methods include decreasing the contact between heptad repeat regions of the protein. The invention provides a peptide including a heptad repeat region of a corona viral spike protein and/or a functional fragment and/or an equivalent thereof. The invention also provides antibodies and inhibiting compounds.
    Type: Application
    Filed: April 14, 2003
    Publication date: April 15, 2004
    Inventors: Petrus Josephus Marie Rottier, Berend-Jan Bosch
  • ANTI-SARS CORONAVIRUS-2 SPIKE PROTEIN ANTIBODIES
    Publication number: 20230295274
    Abstract: Provided are antibodies or antigen binding fragments that specifically recognize a SARS-CoV-2 S protein.
    Type: Application
    Filed: July 27, 2021
    Publication date: September 21, 2023
    Applicant: Single Cell Technology, Inc.
    Inventors: Leyan Tang, Allison Schulkins, Kimberly Than, Chun-Nan Chen
  • Coronavirus vaccine formulations
    Patent number: 10953089
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: March 23, 2021
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
  • Coronavirus vaccine formulations
    Patent number: 11253586
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: February 22, 2022
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
  • ANTIBODIES
    Publication number: 20230265170
    Abstract: The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
    Type: Application
    Filed: February 17, 2023
    Publication date: August 24, 2023
    Inventors: Juthathip MONGKOLSAPAYA, Gavin SCREATON
  • Coronavirus vaccine formulations
    Patent number: 11541112
    Abstract: Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: January 3, 2023
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Michael J. Massare, Jing-Hui Tian
  • CROSS-REACTIVE MONOCLONAL ANTIBODIES AGAINST CORONAVIRUSES
    Publication number: 20240182551
    Abstract: The invention provides antibodies and related antibody agents that are cross-reactive with the spike proteins of multiple human coronaviruses. Also provided in the invention are methods and kits of using such antibodies in various diagnostic and therapeutic applications. In one aspect, the invention provides novel antibodies or antigen-binding fragments thereof that specifically bind to a human coronavirus spike protein.
    Type: Application
    Filed: March 31, 2022
    Publication date: June 6, 2024
    Inventors: Raiees Andrabi, Ge Song, Wanting He, Thomas Rogers, Dennis R. Burton
  • ANTIBODIES
    Publication number: 20220275059
    Abstract: The invention relates to antibodies and antigen-binding fragments thereof that recognize coronavirus spike proteins(CoV-S), such asthe spike protein of Middle East respiratory syndrome coronavirusspike protein(MERS-S). In some embodiments, the antibodiesbind to CoV-Swith high affinity, inhibit CoV infection of human cells, inhibit CoV sialic acid-binding activity and/or bind to multiple types of CoV-S. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating CoV infection.
    Type: Application
    Filed: February 20, 2020
    Publication date: September 1, 2022
    Inventors: Franklin Gerardus GROSVELD, Marinus Johannes VAN HAPEREN, Dubravka DRABEK, Berend Jan BOSCH, Ivy WIDJAJA, Chunyan WANG, Brenda VAN DIEREN, Wentao LI, Frank J.M. VAN KUPPEVELD, Bart L. HAAGMANS, Nisreen M.A. OKBA
  • USNIC ACID, OR INCLUSION COMPLEXES THEREOF, FOR USE IN THE TREATMENT OF INFECTIONS WITH A CORONAVIRUS OR BACTERIA
    Publication number: 20240058297
    Abstract: The present invention relates to a mixture M comprising or, alternatively, consisting of: (a) a usnic acid, and/or (b) a relative salt thereof, and/or (c) an inclusion compound (ci), or mixtures thereof, said inclusion compound (ci) comprising or, alternatively, consisting of: (i) said (a) an usnic acid and/or said (b) a relative salt thereof, and (ii) a cyclodextrin, preferably a beta-cyclodextrin, wherein said mixture M is for use in a method for the treatment of viral infections, advantageously said mixture M being capable of inhibiting the spike protein of a coronavirus. Furthermore, the present invention relates to a composition for use in a treatment method according to the present invention, preferably for oral or nasal use, wherein said composition comprises said mixture M and at least one acceptable pharmaceutical or food grade additive and/or excipient.
    Type: Application
    Filed: December 30, 2021
    Publication date: February 22, 2024
    Inventors: Giorgio Stefano CERANA, Peter BOS, Peter FRANCK, Thomas Detlef BONER
  • S309 CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
    Publication number: 20220184125
    Abstract: Chimeric antigen receptors (CARs) including an scFv binding to coronavirus spike protein (S309 scFv), nucleic acids encoding the CARs, vectors including nucleic acids encoding the CARs, and cells expressing the CARs are provided. Methods of treating a subject with coronavirus are also provided, including administering to the subject a modified immune cell expressing a disclosed CAR.
    Type: Application
    Filed: December 14, 2021
    Publication date: June 16, 2022
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Dongfang Liu, Minh Ma, Saiaditya Badeti
  • CR3022 CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
    Publication number: 20220048978
    Abstract: Chimeric antigen receptors (CARs) including an antigen binding domain specifically binding to coronavirus spike protein, nucleic acids encoding the CARs, vectors including nucleic acids encoding the CARs, and immune cells expressing the CARs are provided. Methods of treating a subject with coronavirus, including administering to the subject an immune cell expressing a disclosed CAR are also provided.
    Type: Application
    Filed: August 11, 2021
    Publication date: February 17, 2022
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Dongfang Liu, Minh Ma, Saiaditya Badeti
  • SARS-COV-2 ANTIBODIES
    Publication number: 20240043506
    Abstract: The present disclosure is directed to isolated or recombinant antigen binding proteins, such as antibodies, which bind to coronavirus spike (S) protein receptor binding domain (RBD), including S protein RBD from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The present disclosure is also directed to the use of the isolated or recombinant proteins as therapeutic, prophylactic and/or diagnostic agents for respiratory conditions associated with coronavirus infection, such as infection by SARS-CoV-2. The present disclosure is also related to nucleic acid sequences which encode said antigen binding proteins and their expression in recombinant host cells.
    Type: Application
    Filed: December 23, 2021
    Publication date: February 8, 2024
    Inventors: Ohan MAZIGI, David LANGLEY, Peter SCHOFIELD, Daniel CHRIST
  • ANTI COVID-19 THERAPIES USING CD40 LIGAND FUSION PROTEIN
    Publication number: 20210284713
    Abstract: Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a extracellular portion of CD40 ligand (CD40L) coupled by a flexible linker to a coronavirus 2 (CoV2) spike protein and/or a CoV2 nucleocapsid protein.
    Type: Application
    Filed: October 28, 2020
    Publication date: September 16, 2021
    Inventors: Kayvan Niazi, Jay Gardner Nelson, Annie Shin, Clifford Anders Olson, Shiho Tanaka
  • SPECIFICITY ENHANCING REAGENTS FOR COVID-19 ANTIBODY TESTING
    Publication number: 20230168247
    Abstract: Methods of detecting SARS-CoV-2 antibodies with improved specificity are described. The methods can include contacting a sample potentially containing SARS-CoV-2 antibodies with a reagent to remove non-anti-SARS-CoV-2 antibodies, such as a reagent comprising an epitope from a nucleocapsid protein or spike protein of a common coronavirus. The methods can include contacting the sample with a mutant SARS-CoV-2 nucleocapsid protein or spike protein comprising a reduced number of common coronavirus epitopes. The methods can involve comparing results from an immunoassay performed with a SARS-CoV-2 protein to results obtained from immunoassays performed with analogous protein from one or more common coronaviruses.
    Type: Application
    Filed: April 26, 2021
    Publication date: June 1, 2023
    Applicant: University of Virginia Patent Foundation
    Inventors: James C. Zimring, Lindsay Ann Legendre Bazydlo, Joesph Richard Wiencek, James David Gorham, Heather Howie
  • VACCINE COMPOSITION FOR PREVENTING OR TREATING INFECTION OF SARS-COV-2
    Publication number: 20230257425
    Abstract: Provided is a recombinant protein for preventing or treating infection of SARS-Coronavirus-2 antigen comprising an extended receptor binding domain (RBD) of a spike protein of SARS-Coronavirus-2, and a vaccine composition comprising thereof. Also the present invention relates to a method for preventing infection of SARS-Coronavirus-2 by administering the recombinant antigen protein to a subject. The present invention can prevent COVID-19 infection. The present invention can be used as a vaccine.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 17, 2023
    Inventors: Teawoo KWON, YoonJae LEE, Eun-som KIM, Seung-hye HONG, Ki-weon SEO, Sujeen LEE
  • METHODS AND COMPOSITIONS FOR TREATING INFECTIONS
    Publication number: 20220233683
    Abstract: The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-CoV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 28, 2022
    Inventor: Barbara L. Hibner
  • BINDING MOLECULE HAVING NEUTRALIZING ACTIVITY AGAINST SARS-CORONAVIRUS-2
    Publication number: 20230113734
    Abstract: The present invention relates to a binding molecule that binds to SARS-coronavirus-2 (SARS-CoV-2). More particularly, the binding molecule of the present invention has strong ability to bind to a spike protein (S protein) on the surface of SARS-coronavirus-2 and high neutralizing activity against SARS-coronavirus-2 and is thus very useful in the diagnosis, prevention or treatment of SARS-coronavirus infection (COVID-19).
    Type: Application
    Filed: March 22, 2021
    Publication date: April 13, 2023
    Inventors: Cheol-Min KIM, Ji-Min SEO, Min-Soo KIM, Soo-Young LEE, Dong-Kyun RYU, Sung-Soon KIM, Joo-Yeon LEE, Kyung-Chang KIM, Jeong-Sun YANG, Han-Saem LEE, Hye-Min WOO, Jun-Won KIM
  • CORONAVIRUS VACCINES AND USES THEREOF
    Publication number: 20230015616
    Abstract: This disclosure relates to coronavirus vaccines and uses thereof. In one aspect, the disclosure provides a nucleic acid vaccine, comprising a sequence encoding a spike protein or fragment thereof derived from a coronavirus.
    Type: Application
    Filed: November 30, 2020
    Publication date: January 19, 2023
    Inventors: Bill Biliang ZHANG, Man LI, Lin MA, Jian WEN, Hong ZHANG, Huiling ZHONG
  • LICHENASE-COVID-19 BASED VACCINE
    Publication number: 20210283243
    Abstract: The present invention includes an immunogenic protein, nucleic acid, plant and immunization comprising a fusion protein that has at least 90% amino acid identity to an amino acid sequence of a modified thermostable lichenase (LicKM) polypeptide as set forth in SEQ ID NO:9, wherein the LicKM polypeptide comprises an N-terminus, a C-terminus, and an inner loop region, and wherein a Receptor Binding Domain (RBD) or a Receptor Binding Motif (RBM) of a coronavirus spike protein is positioned at, at least one of, the N-terminus, the C-terminus, or in a loop region of the LicKM polypeptide.
    Type: Application
    Filed: March 11, 2021
    Publication date: September 16, 2021
    Inventor: Sylvain Marcel
Narrow Results

Filter by US Classification